Emergex Signs Agreement with George Mason University for Highly Pathogenic RNA Virus Studies
by Press Release from Outbreak News Today on (#52J2G)
Emergex Vaccines Holding Limited, a biotechnology company developing CD8+ priming set-point vaccines to prevent serious infectious diseases, today announced that it has entered into an agreement with the George Mason University, based in Virginia, in the United States. The agreement specifies that George Mason University's National Center for Biodefense and Infectious Diseases will provide their ["]
The post Emergex Signs Agreement with George Mason University for Highly Pathogenic RNA Virus Studies appeared first on Outbreak News Today.